[ad_1] Phase 3b DAYLIGHT study being presented at ESG 2023 demonstrated fezolinetant 45 mg achieved statistically significant reductions in the frequency and severity of moderate to severe vasomotor symptoms due…
Tag: Astellas
Pfizer and Astellas’ XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
[ad_1] XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy* in nonmetastatic castration-sensitive prostate cancer TOKYO and NEW YORK,…
Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant)
[ad_1] Fezolinetant is an investigational nonhormonal treatment for vasomotor symptoms (VMS) associated with menopause More than half of women ages 40 to 64 worldwide experience VMS, with rates in Europe…
Health News Roundup: Swine fever detected in Sweden for the first time; AT&T says tests at some lead cable sites show no public health risk and more
[ad_1] Following is a summary of current health news briefs. Swine fever detected in Sweden for the first time A dead wild boar in Sweden has tested positive for African…
Recon: FDA declines to approve Ascendis’ hypoparathyroidism drug; Astellas to buy Iveric for $5.9B
[ad_1] Recon | 01 May 2023 | By Joanne S. Eglovitch Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. In Focus: US FDA advisory committee votes against plan…
Japan’s Astellas to buy US biotech group Iveric Bio for $5.9bn
[ad_1] Astellas Pharma has agreed to buy US biotech group Iveric Bio for roughly $5.9bn, marking the Japanese drugmaker’s largest-ever acquisition and giving it access to the rapidly expanding market…
Astellas Pharma to Buy Iveric Bio for About $5.9B
[ad_1] The Japanese drugmaker said it agreed to acquire Iveric bio for about $5.9 billion to strengthen its capabilities in the ophthalmology field. [ad_2] Source link
Astellas Enters into Definitive Agreement to Acquire Iveric Bio
[ad_1] -Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023– -Acquisition advances Astellas’ Primary…